The mixed earnings report from Y-mAbs Therapeutics, with an EPS beat but a miss on sales forecasts, presents a neutral outlook. The EPS beat may provide some positive sentiment, but the miss on sales and slight year-over-year decrease could temper any potential gains. Given the mixed nature of the report, the short-term impact on the stock price is likely to be neutral as investors digest both the positive and negative aspects of the earnings.